Publications
Detailed Information
Effect of olmesartan and amlodipine on serum angiotensin-(1–7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyuho | - |
dc.contributor.author | Moon, Ji Hye | - |
dc.contributor.author | Ahn, Chang Ho | - |
dc.contributor.author | Lim, Soo | - |
dc.date.accessioned | 2023-05-11T04:56:12Z | - |
dc.date.available | 2023-05-11T13:57:00Z | - |
dc.date.issued | 2023-03-11 | - |
dc.identifier.citation | Diabetology & Metabolic Syndrome, 15(1):43 | ko_KR |
dc.identifier.issn | 1758-5996 | - |
dc.identifier.uri | https://hdl.handle.net/10371/192365 | - |
dc.description.abstract | Background
Recent studies suggest that angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) [Ang-(1–7)] might have beneficial effects on the cardiovascular system. We investigated the effects of olmesartan on the changes in serum ACE2 and Ang-(1–7) levels as well as kidney and vascular function in patients with type 2 diabetes and hypertension. Methods This was a prospective, randomized, active comparator-controlled trial. Eighty participants with type 2 diabetes and hypertension were randomized to receive 20mg of olmesartan (N = 40) or 5mg of amlodipine (N = 40) once daily. The primary endpoint was changes of serum Ang-(1–7) from baseline to week 24. Results Both olmesartan and amlodipine treatment for 24weeks decreased systolic and diastolic blood pressures significantly by > 18mmHg and > 8mmHg, respectively. Serum Ang-(1–7) levels were more significantly increased by olmesartan treatment (25.8 ± 34.5pg/mL → 46.2 ± 59.4pg/mL) than by amlodipine treatment (29.2 ± 38.9pg/mL → 31.7 ± 26.0pg/mL), resulting in significant between-group differences (P = 0.01). Serum ACE2 levels showed a similar pattern (6.31 ± 0.42ng/mL → 6.74 ± 0.39ng/mL by olmesartan treatment vs. 6.43 ± 0.23ng/mL → 6.61 ± 0.42ng/mL by amlodipine treatment; P < 0.05). The reduction in albuminuria was significantly associated with the increases in ACE2 and Ang-(1–7) levels (r = − 0.252 and r = − 0.299, respectively). The change in Ang-(1–7) levels was positively associated with improved microvascular function (r = 0.241, P < 0.05). Multivariate regression analyses showed that increases in serum Ang-(1–7) levels were an independent predictor of a reduction in albuminuria. Conclusions These findings suggest that the beneficial effects of olmesartan on albuminuria may be mediated by increased ACE2 and Ang-(1–7) levels. These novel biomarkers may be therapeutic targets for the prevention and treatment of diabetic kidney disease. Trial registration: ClinicalTrials.gov NCT05189015. | ko_KR |
dc.description.sponsorship | This research was funded by Daiichi Sankyo Co., Seoul, South Korea through a subcontract with SNUBH (Seongnam, Republic of Korea). The funding agency had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Angiotensin-converting enzyme 2 | - |
dc.subject | Angiotensin-(1–7) | - |
dc.subject | Olmesartan | - |
dc.subject | Amlodipine | - |
dc.subject | Albuminuria | - |
dc.title | Effect of olmesartan and amlodipine on serum angiotensin-(1–7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1186/s13098-023-00987-1 | ko_KR |
dc.citation.journaltitle | Diabetology & Metabolic Syndrome | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2023-03-30T09:52:49Z | - |
dc.citation.number | 43 | ko_KR |
dc.citation.volume | 15 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.